ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2244

Can Achieving Remission Improve Work Ability and Quality of Life in Early Rheumatoid Arthritis (RA) Patients? a Prospective Cohort Study

Ho Man Lam1, Tsz Ho CHENG2 and Lai-Shan Tam1, 1Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong, 2Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Health Assessment Questionnaire, quality of life and rheumatoid arthritis (RA), Work Disability

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 7, 2017

Title: Patient Outcomes, Preferences, and Attitudes Poster III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: RA patients often suffer from impaired work ability and reduced health related quality of life (HRQoL). Whether achieving remission through tight-control treatment strategy using conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs) can improve work ability and HRQoL remains unclear. The aim of this study was to ascertain whether achieving remission can improve work ability and quality of life in early RA patients.

 

Methods: Early RA patients with symptom onset <2 years were recruited. All patients satisfied the 2010 ACR-EULAR classification criteria for RA (>=6 points). Remission status was measured by Disease Activity Score 28 (DAS28) and Simple Disease Activity Index (SDAI) every 3 months. Work ability was evaluated by working ability index (WAI) compared to life time best (score from 0-10, with 10 as best). HRQoL was assessed by 36-Item Short Form Survey (SF-36), Health Assessment Questionnaire Disability Index (HAQ-DI), Functional Assessment of Chronic Illness Therapy (FACIT) and EuroQol five dimensions questionnaire (EQ-5D).

Results: A total of 199 (51}13 years old, 158[79.4%] female, 146[73.4%] employed) patients completed one year follow up. At baseline, unemployed patients have a higher physician global assessment score, more swollen joints, lower WAI, lower EQ-5D and higher HAQ-DI (Table1). Using multivariate linear regression, achieving DAS28 and SDAI remission at ≥ 2 visits are independent predictors for better WAI, HRQoL, HAQ, FACIT and EQ5D at one year after adjustment for other covariates (Table2). Achieving remission only once in the first year was not associated with improvement in WAI.

Conclusion: Achieving at least two time remissions is important in improving patientsf work ability and HRQoL.

 



Disclosure: H. M. Lam, None; T. H. CHENG, None; L. S. Tam, None.

To cite this abstract in AMA style:

Lam HM, CHENG TH, Tam LS. Can Achieving Remission Improve Work Ability and Quality of Life in Early Rheumatoid Arthritis (RA) Patients? a Prospective Cohort Study [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/can-achieving-remission-improve-work-ability-and-quality-of-life-in-early-rheumatoid-arthritis-ra-patients-a-prospective-cohort-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/can-achieving-remission-improve-work-ability-and-quality-of-life-in-early-rheumatoid-arthritis-ra-patients-a-prospective-cohort-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology